Monitor Pharma Direct segment growth as the company's key strategic pivot, but expect continued pressure on core prescription and subscription revenue. The significant guidance cut suggests structural challenges in the retail pharmacy landscape will persist into 2026.
Price Chart
Executive Summary
GoodRx reported in-line Q4 and full-year 2025 results with $796.9M revenue (+1% YoY) and $270.5M Adjusted EBITDA. Key growth driver Pharma Direct revenue grew 41% YoY. However, the company issued bearish 2026 guidance projecting revenue of $750-780M (-6% to -2% YoY) and Adjusted EBITDA of $230M (-15% YoY), citing ongoing retail pharmacy challenges.
Key Financial Metrics
Key Facts
- Full year 2025 revenue: $796.9M (+1% YoY)
- Pharma Direct revenue: $151.4M (+41% YoY)
- 2026 revenue guidance: $750-780M (-6% to -2% YoY)
- 2026 Adjusted EBITDA guidance: $230M (-15% YoY)
- Subscription revenue declined 3% YoY to $83.8M
- Prescription transactions revenue declined 6% YoY to $544M
Financial Impact
Revenue projected to decline 2-6% in 2026 with 15% drop in Adjusted EBITDA
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Prescription transactions | $544.0M | -6.0% |
| Subscription | $83.8M | -3.0% |
| Pharma Direct | $151.4M | +41.0% |
Risk Factors
- Continued decline in prescription transaction volume
- Failure to offset core business declines with Pharma Direct growth
- Ongoing retail pharmacy store closures impacting consumer access
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001809519-26-000028 |
| Document: gdrx-20260225.htm | 0001809519-26-000028 |
| Document: 0001809519-26-000028-index-headers.html | 0001809519-26-000028 |
| Document: 0001809519-26-000028-index.html | 0001809519-26-000028 |
| Document: 0001809519-26-000028.txt | 0001809519-26-000028 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 4w ago | Institutional Cluster | $3.44 $3.52 | ▲ +2.33% | ▲ +2.89% | $3.50 (+1.74%) |
Aug 19, 2026 9w ago | 144 | $3.54 $3.40 | ▲ +3.95% | ▲ +2.00% | $3.50 (+1.13%) |
May 6, 2026 24w ago | 8-K | $2.84 $2.81 | ▼ −1.06% | ▼ −4.19% | $3.50 (+23.24%) |
Apr 24, 2026 26w ago | 8-K | $2.28 $2.78 | ▲ +21.93% | ▲ +16.97% | $3.50 (+53.51%) |
Apr 3, 2026 29w ago | 8-K | $2.07 $2.50 | ▲ +20.77% | ▲ +11.79% | $3.50 (+69.08%) |
Feb 25, 2026 34w ago | 8-K | $1.99 $2.04 | ▼ −2.51% | ▼ −8.91% | $3.50 (−75.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers